ArticleNature medicine2022
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
Erratum issued 8 registry-linked trialsAbstract read
In one paragraph
Article in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 8 registered trials, which are not on this map. Cited by 580 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
580citing papers in PubMed, 5 pooled it
85.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT05938725 phase1 / phase2active not recruitingnot on this mapstarted 2023, after this paper: background citation
KYSA-1: A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
A Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
NCT06222853 phase1active not recruitingnot on this mapstarted 2024, after this paper: background citation
A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T Cell Injection Targeting CD19 Gene in the Treatment of Refractory Systemic Lupus Erythematosus
Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus Single Arm Phase I and Phase II Randomized Controlled Open, Multicenter Study
KYSA-3: A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
NCT06475495 phase1 / phase2active not recruitingnot on this mapstarted 2024, after this paper: background citation
Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis. Two-stage Interventional, Prospective, Randomized, Controlled, Open Label, Parallel-group Phase I/II Trial in Patients With Active, ACPA-positive and Treatment Refractory Rheumatoid Arthritis
NCT06590545 phase1 / phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation
Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis: a Two-stage Interventional, Prospective, Open-label, Phase I/II Trial in Patients With Active, Treatment Refractory, ANCA-IgG-positive Vasculitis
Study of BCMA/CD70 Targeted Chimeric Antigen Receptor T (CAR- T) Therapy for Refractory Childhood-oneset Systemic Lupus Erythematosus
Who cites it
580 citing papers in PubMed, 5 syntheses or guidelines pooled it, 903 citations in OpenAlex.
- Safety profiles of CAR-T cell therapy in systematic autoimmune diseases: a systematic review and analysis.Immunologic research · 2026Pooled it
- A new hope with CAR T-cell therapy for refractory idiopathic inflammatory myopathies: a systematic review.Journal of translational medicine · 2026Pooled it
- B-cell centrality dictates therapeutic efficacy across autoimmune diseases: a systematic review.Frontiers in immunology · 2026Pooled it
- CAR T cell therapy efficacy and safety in SLE: a systematic review and pooled analysis of 47 patients across 10 studies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- CAR-based cellular therapy for refractory systemic lupus erythematosus: an overlap-controlled systematic review.Frontiers in immunology · 2026Pooled it
- A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.Nature communications · 2026Trial
- BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.Nature medicine · 2026Trial
- CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.Nature medicine · 2026Trial
- Review
- Cytokine co-presentation on targeted lipid nanoparticles enhances in vivo T cell engineering.Biomaterials · 2027Article
- In vivo immune cell engineering from bench to clinical reality.Pharmaceutical science advances · 2026Review
- Chimeric antigen receptor T-cell therapy in systemic lupus erythematosus: From B cell depletion to immune reprogramming.Journal of translational autoimmunity · 2026Review
- B-cell-targeting therapies in podocytopathies.Pediatric nephrology (Berlin, Germany) · 2026Review
- Interferon regulatory factors orchestrate CD8International journal of molecular medicine · 2026Review
- Autoimmune-associated thrombosis: mechanisms, population burden, and prevention strategies.The Lancet regional health. Europe · 2026Review
- Current and Emerging Therapies for Generalized Myasthenia Gravis: Toward Precision Medicine.Neurology and therapy · 2026Review
- Cardiovascular Toxicity Across the Cancer Immunotherapy Spectrum: Mechanisms and Management in Immune Checkpoint Inhibitor (ICI) and Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.Current oncology reports · 2026Review
- CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial.Nature medicine · 2026Article
- Chimeric Antigen Receptor T-cell therapy in systemic lupus erythematosus and other autoimmune diseases: a literature review.Journal of rheumatic diseases · 2026Review
- Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.Signal transduction and targeted therapy · 2026Review
520 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
24 authors at 2 institutions in 1 country.
Andreas Mackensen *Department of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0002-0685-4483
Fabian Müller *Department of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Dimitrios Mougiakakos *Department of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Sebastian BöltzDeutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0001-5227-8707
Artur WilhelmDeutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0002-4637-1582
Michael AignerDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Simon VölklDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
David SimonDeutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0001-8310-7820
Arnd KleyerDeutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0002-2026-7728
Luis MunozDeutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Sascha KretschmannDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Soraya KharboutliDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Regina GaryDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Hannah ReimannDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0002-7336-2008
Wolf RöslerDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Stefan UderhardtDeutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Holger BangOrgentec, Mainz, Germany.
Martin HerrmannDeutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0002-0258-2484
Arif Bülent EkiciInstitute of Human Genetics, Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0001-6099-7066
Christian BuettnerInstitute of Human Genetics, Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Katharina Marie HabenichtDivision of Genetics, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Thomas H WinklerDivision of Genetics, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany.ORCID http://orcid.org/0000-0002-1860-0528
Gerhard Krönke *Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0002-7566-4325
Georg Schett *Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany. georg.schett@uk-erlangen.de.ORCID http://orcid.org/0000-0001-8740-9615
Universitätsklinikum Erlangen · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a life-threatening autoimmune disease characterized by adaptive immune system activation, formation of double-stranded DNA autoantibodies and organ inflammation. Five patients with SLE (four women and one man) with a median (range) age of 22 (6) years, median (range) disease duration of 4 (8) years and active disease (median (range) SLE disease activity index Systemic Lupus Erythematosus Disease Activity Index: 16 (8)) refractory to several immunosuppressive drug treatments were enrolled in a compassionate-use chimeric antigen receptor (CAR) T cell program. Autologous T cells from patients with SLE were transduced with a lentiviral anti-CD19 CAR vector, expanded and reinfused at a dose of 1 × 10
Indexed as
Lupus Erythematosus, SystemicReceptors, Chimeric AntigenAntigens, CD19AutoantibodiesChildCyclophosphamideCytokinesFemaleHumansImmunotherapy, AdoptiveMaleReceptors, Antigen, B-CellAntigens, CD19AutoantibodiesCyclophosphamideCytokinesReceptors, Antigen, B-CellReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT05938725ClinicalTrials.gov
NCT06138132ClinicalTrials.gov
NCT06222853ClinicalTrials.gov
NCT06297408ClinicalTrials.gov
NCT06342960ClinicalTrials.gov
NCT06475495ClinicalTrials.gov
and 2 more above
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.